Liu Jing, Hu Xiaoping, Luo Kaixiu, Xiong Yan, Chen Li, Wang Zhen, Inuzuka Hiroyuki, Qian Chao, Yu Xufen, Xie Ling, Muneer Adil, Zhang Dingpeng, Paulo Joao A, Chen Xian, Jin Jian, Wei Wenyi
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, United States.
Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
J Am Chem Soc. 2024 Apr 10. doi: 10.1021/jacs.4c02373.
Deubiquitinase-targeting chimeras (DUBTACs) have been recently developed to stabilize proteins of interest, which is in contrast to targeted protein degradation (TPD) approaches that degrade disease-causing proteins. However, to date, only the OTUB1 deubiquitinase has been utilized to develop DUBTACs via an OTUB1 covalent ligand, which could unexpectedly compromise the endogenous function of OTUB1 owing to its covalent nature. Here, we show for the first time that deubiquitinase USP7 can be harnessed for DUBTAC development. Based on a noncovalent ligand of USP7, we developed USP7-based DUBTACs that stabilized the ΔF508-CFTR mutant protein as effectively as the previously reported OTUB1-based DUBTAC. Importantly, using two different noncovalent ligands of USP7, we developed the first AMPK DUBTACs that appear to selectively stabilize different isoforms of AMPKβ, leading to elevated AMPK signaling. Overall, these results highlight that, in addition to OTUB1, USP7 can be leveraged to develop DUBTACs, thus significantly expanding the limited toolbox for targeted protein stabilization and the development of novel AMPK DUBTACs as potential therapeutics.
靶向去泛素化酶嵌合体(DUBTACs)是最近开发出来用于稳定目标蛋白的,这与降解致病蛋白的靶向蛋白降解(TPD)方法形成对比。然而,迄今为止,只有OTUB1去泛素化酶被用于通过OTUB1共价配体开发DUBTACs,由于其共价性质,这可能意外损害OTUB1的内源性功能。在此,我们首次表明去泛素化酶USP7可用于开发DUBTACs。基于USP7的非共价配体,我们开发了基于USP7的DUBTACs,其稳定ΔF508-CFTR突变蛋白的效果与先前报道的基于OTUB1的DUBTAC一样有效。重要的是,使用USP7的两种不同非共价配体,我们开发了首个AMPK DUBTACs,它们似乎能选择性地稳定AMPKβ的不同亚型,从而导致AMPK信号增强。总体而言,这些结果突出表明,除了OTUB1之外,USP7也可用于开发DUBTACs,从而显著扩展了用于靶向蛋白稳定的有限工具库,并开发出新型AMPK DUBTACs作为潜在疗法。